KRAS and non-small cell lung carcinoma: Another selective, covalent, and irreversible KRAS G12C inhibitor, JDQ443, is under investigation in a phase Ib/II trial (KontRASt-01; NCT04699188) as monotherapy or in combination with TNO155 (SHP2 inhibitor) and/or tislelizumab (anti–PD-1 monoclonal antibody) in KRAS G12C-mutated solid tumors, including non-small cell lung cancer.